A neoantigen vaccine generates antitumour immunity in renal cell carcinoma
Nature, Published online: 05 February 2025; doi:10.1038/s41586-024-08507-5A phase I trial of a neoantigen-targeting personalized cancer vaccine led to durable and polyfunctional T cell responses and antitumour recognition, and was associated with no recurrence in patients with high-risk clear cell renal cell carcinoma.
Nature, Published online: 05 February 2025; doi:10.1038/s41586-024-08507-5A phase I trial of a neoantigen-targeting personalized cancer vaccine led to durable and polyfunctional T cell responses and antitumour recognition, and was associated with no recurrence in patients with high-risk clear cell renal cell carcinoma.
